MDNA 19
Alternative Names: IL-2 superkine program - Medicenna Therapeutics; MDNA 109 LA1; MDNA-19Latest Information Update: 28 Oct 2023
At a glance
- Originator Medicenna Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 12 Apr 2021 Pharmacodynamics data from preclinical trial in cancer released by Medicenna Therapeutics
- 15 May 2020 Medicenna Therapeutics expects to file an IND for Cancer in first quarter of 2021